AMD & Geographic Atrophy Tool Kit
Give your patients every opportunity to access the exciting new era of AMD treatment and care with Advanced RPE Analysis and ZEISS AngioPlex, the AMD & Geographic Atrophy Tool Kit from ZEISS CIRRUS.
Age-related macular degeneration (AMD) is the leading cause of severe, irreversible vision loss in people over age 60, and it is growing at an alarming rate all over the world. Your patients may be at risk. It is estimated that 196 million people had AMD in 2020, with that number rising to 288 million by 2040, yet 25% of AMD in the primary eyecare setting goes undiagnosed.1,2 That's over 46% increase - 92 million more people who may be at risk of losing their vision, and they have no idea it’s even happening. We can help them. Learn how to utilize Advanced RPE Analysis and AngioPlex® together as an AMD and Geographic Atrophy Tool Kit for the diagnosis and management of your AMD patients.
It is estimated that 196 million people worldwide had AMD in 2020.
AMD affects central vision and 92 million more people may be at risk of sight loss.
Adults age 60+ are at a higher risk for developing AMD.
Smoking, family history, unhealthy diet, inactivity and exposure to sunlight are some of the risk factors for developing AMD.
A new era in geographic atrophy
The role of OCT
Advanced RPE Analysis
Quantitative measurement and historical data comparison
The Advanced RPE Analysis, available on the ZEISS CIRRUS OCT, was specifically created to help clinicians manage non-neovascular AMD in all its forms.
Importance of early progression detection
OCT angiography (OCTA) systems such as the ZEISS CIRRUS AngioPlex®, continue to push the boundaries of ocular imaging so that clinicians can better care for these patients.
A collaborative care model
Optimizing patient outcomes
The ZEISS CIRRUS OCT with its Advanced RPE Analysis and AngioPlex® can provide the foundation on which optometrists and ophthalmologists can detect and monitor all forms of AMD.
Wong, Wan Ling, et al. "Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis." The Lancet Global Health 2.2 (2014): e106-e116
Neely DC, Bray KJ, Huisingh CE, et al. Prevalence of undiagnosed age-related macular degeneration in primary eye care. JAMA Ophthalmol. 2017;135(6):570-5